ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

Inclusion Criteria:

1. Participants ≥ 18 years of age

2. Have a diagnosis of plaque psoriasis for > 6 months

3. Have moderate-to-severe chronic plaque psoriasis defined as:

4. BSA ≥ 10%, and

5. PASI ≥ 12, and

6. IGA score of ≥ 3 on a 5-point scale

7. Candidate for systemic therapy or phototherapy

8. Women of childbearing potential must have a negative pregnancy test

Exclusion Criteria:

1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) ordrug-induced psoriasis

2. Significant history or clinical manifestation of any metabolic, otherdermatological, hepatic, renal, hematologic, pulmonary, cardiovascular,gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, orany infectious disease

3. History of malignancy, except for non-melanoma skin cancer or cancer curativelytreated ≥ 5 years, without evidence of recurrence

4. A known hypersensitivity to any components of the ORKA-001 drug product

5. Women who are breastfeeding or plan to breastfeed during the study